TABLE 2-1 Brief Characterization of 13 Secondary Resources and How They Meet the Described Considerations
|
|
Resource |
|
|
Considerations |
Agency for Healthcare Research and Quality (AHRQ) (AHRQ, 2000a, 2000b, 2002b, 2003a) |
American Herbal Pharmacopoeia (AHP, 2002, 2004a, 2004b; Upton, 1997, 1999) (Reviewed St. Johns Wort and Valerian Root monographs) |
|
Type of organization responsible for resource |
U.S. government |
Private, nonprofit organization |
|
Substances reviewed techniques, practices, |
Many health care and substances, including several dietary supplements |
Botanicals commonly used in the United States; selections are based on recommendations of a prioritization committee or monograph sponsorship from interested organizations or companies |
|
Product/endpoint |
Meta-analysis published when completed |
Summary monographs |
|
Focus on safety/risk |
Both efficacy and safety are considered |
Identification, handling, standardization, and analytical methods are discussed; safety and efficacy information are considered |
|
Reliance on primary data |
Primary sources are cited, including foreign language sources |
Primary and secondary sources are used, including foreign language articles |
|
Use of nonhuman data |
Only human data are considered in the examples reviewed |
Human, animal, and in vitro information are used in efficacy assessment; however, from the examples reviewed, it is not clear the degree to which various types of information are generally used |
|
Description of limitations |
Limitations are described: a summary of challenges in conducting and interpreting the research is given, difficulties in obtaining and interpreting adverse events are explained |
The material examined includes limitations as described by the authors of the primary sources |